Hetero Drugs Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 3.45 Cr
- Company Age 31 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 955.81 Cr
- Satisfied Charges ₹ 3,560.31 Cr
- Revenue Growth 19.76%
- Profit Growth 65.07%
- Ebitda 13.14%
- Net Worth 8.05%
- Total Assets 8.62%
About Hetero Drugs
Hetero Drugs Limited (HDL) is a leading Public Limited Indian Non-Government Company incorporated in India on 06 April 1993 and has a history of 31 years and ten months. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Hetero Drugs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 3.45 Cr.
The company currently has active open charges totaling ₹955.81 Cr. The company has closed loans amounting to ₹3,560.31 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Hetero Drugs Limited India is Ravi Upputhalla as COMPANY SECRETARY. Parthasaradhi Bandi, Attunuri Reddy, Kalavathi Bandi, and Five other members serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG1993PLC015582
- Company No.
015582
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
06 Apr 1993
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Hetero Drugs Limited offer?
Hetero Drugs Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Antiviral Drugs, HIV Drugs, Digestive System Drugs & Medicines, Gastrointestinal Drugs, Pharma & Bioanalytical Services, PCD Pharma Franchise, Apparel & Textile Machinery, Textile Finishing Machine.
Who are the key members and board of directors at Hetero Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Upputhalla  | Company Secretary | 03-Sep-2018 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Parthasaradhi Bandi | Director | 01-Apr-2008 | Current |
| Attunuri Reddy | Director | 28-Jan-1999 | Current |
| Kalavathi Bandi | Director | 01-Apr-2015 | Current |
| Sambi Jonnala | Whole-Time Director | 18-Nov-1999 | Current |
| Rathnakar Kura | Director | 28-Nov-2013 | Current |
| Bandi Vamsikrishna | Director | 10-Apr-2008 | Current |
Financial Performance of Hetero Drugs.
Hetero Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.76% increase. The company also saw a substantial improvement in profitability, with a 65.07% increase in profit. The company's net worth moved up by a moderate rise of 8.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hetero Drugs?
In 2023, Hetero Drugs had a promoter holding of 76.24% and a public holding of 23.76%. The company had 5 Subsidiaries and 3 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hindys Lab Private LimitedSambi Jonnala is a mutual person
Hetero Marbles Private LimitedBandi Vamsikrishna is a mutual person
Hetero Labs LimitedParthasaradhi Bandi, Attunuri Reddy and 2 more are mutual person
- Hetero Biopharma Limited
Parthasaradhi Bandi and Bandi Vamsikrishna are mutual person
- Hetero Wind Power Limited
Kalavathi Bandi and Bandi Vamsikrishna are mutual person
- Hetero Infrastructure Sez Private Limited
Sambi Jonnala and Rathnakar Kura are mutual person
Charges (Loans)
₹955.81 Cr
₹3,560.31 Cr
Charges Breakdown by Lending Institutions
- Idbi Trusteeship Services Limited : 700.00 Cr
- State Bank Of India : 150.00 Cr
- Industrial Development Bank Of India : 81.00 Cr
- Idbi Bank : 15.61 Cr
- Others : 6.14 Cr
- Others : 3.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Mar 2024 | State Bank Of India | ₹150.00 Cr | Open |
| 23 Jan 2023 | Others | ₹0.90 M | Open |
| 29 Sep 2022 | Others | ₹1.06 M | Open |
| 29 Sep 2022 | Others | ₹1.10 M | Open |
| 27 Jul 2022 | Others | ₹1.57 Cr | Open |
How Many Employees Work at Hetero Drugs?
Hetero Drugs has a workforce of 1711 employees as of Jul 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hetero Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hetero Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
